Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxidectin in Loa loa microfilaremic patients
NCT04049851Phase 2Completed
- Start
- Apr 2022
- Primary completion
- Jul 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of moxidectin in loiasis (2 arms). Primary endpoints: Incidence of severe adverse events at 1 week and Incidence of adverse events at 1 week. Started Apr 2022; status: completed.
02
Drugs
moxidectin
03
Conditions
loiasis
Beyond the preview
Go deeper on NCT04049851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049851.